Elsevier

Clinics in Liver Disease

Volume 12, Issue 3, August 2008, Pages 693-712
Clinics in Liver Disease

Hepatitis C Virus Entry and Neutralization

https://doi.org/10.1016/j.cld.2008.03.008Get rights and content

The processes of hepatitis C virus (HCV) entry and antibody-mediated neutralization are intimately linked. The high frequency of neutralizing antibodies (nAbs) that inhibit E2-CD81 interaction(s) suggests that this is a major target for the humoral immune response. The observation that HCV can transmit to naive cells by means of CD81-dependent and -independent routes in vitro awaits further investigation to assess the significance in vivo but may offer new strategies for HCV to escape nAbs. The identification of claudins in the entry process highlights the importance of cell polarity in defining routes of HCV entry and release, with recent experiments suggesting a polarized route of viral entry into cells in vitro. In this review, the authors summarize the current understanding of the mechanism(s) defining HCV entry and the role of nAbs in controlling HCV replication.

Section snippets

Tools to study hepatitis C virus entry

Currently, there are two methods for studying HCV entry. The first is based on the capacity of retroviruses lacking endogenous glycoproteins (gps) to incorporate foreign envelope proteins. The resulting pseudoparticles infect cells in a manner that is defined by the heterologous encoded gps. HCV encodes two gps, E1 and E2, and their detailed processing and biogenesis have been reviewed elsewhere [4]. The pseudotyping approach has allowed the characterization of viruses bearing a range of HCV

Elucidation of the receptors defining hepatitis C virus attachment and internalization

HCVpp entry into hepatoma cell lines and primary human hepatocytes is via pH-dependent clathrin-mediated endocytosis [17], [18]. Current evidence suggests that at least three host cell molecules are important for HCV entry in vitro: the tetraspanin CD81 [5], [9], [13], [19], scavenger receptor class B member I (SR-BI) [9], [20], [21], [22], and the tight junction (TJ) protein claudin-1 (CLDN1) [23]. Other factors, such as glycosaminoglycans (GAGs) [24], [25] and low-density lipoprotein (LDL)

Scavenger receptor class B member I

The first evidence for a role of SR-BI in HCV entry was the demonstration that sE2 bound to CD81-negative HepG2 cells by means of SR-BI [20]. SR-BI is the major receptor for high-density lipoprotein (HDL) and is involved in the trafficking of cholesterol into hepatocytes by means of selective uptake from cholesterol-rich lipoproteins and by the uptake of HDL particles into endosomes. The role of SR-BI in lipid physiology was recently reviewed [57]. Unlike CD81, which is expressed ubiquitously,

Tight junction claudin proteins

An additional host cell molecule reported to be important for HCV entry was recently identified as the TJ protein CLDN1 [78]. TJs are continuous intercellular contacts at the apical poles of lateral cell membranes that form a barrier to regulate the paracellular transit of solutes across a cell layer and to establish cell polarity [79]. The CLDN family of transmembrane proteins extends into the paracellular space, wherein they form homo- and heteroassociations with CLDNs on apposing cells [80].

Role of cell polarization in hepatitis C virus infection

Many tissues in the body contain polarized cells, and hepatocytes in the liver are known to be polarized, with TJs separating the apical (canalicular) and basolateral (sinusoidal) domains. Hepatic polarity is critical for normal liver function, with particular membrane domains performing specific tasks, such as biliary secretion from the canaliculi and serum protein secretion from the sinusoidal surface(s). To initiate infection, pathogens must breach the epithelial barrier to gain access to

Humoral immune response in hepatitis C virus infection

HCV-infected individuals often have detectable RNA levels as early as 1 week after infection; however, antibodies against the virus are not detected until much later. Chen and colleagues [94] noted the delayed appearance, low titer, and restricted isotype of antibodies to structural and nonstructural HCV proteins. The contribution of the humoral response to disease outcome remains unclear; in contrast, it has been well documented that a potent multi-specific and long-lasting cellular immune

In vitro systems for the measurement of neutralizing antibodies

Before the development of in vitro infection systems, the neutralization potential of HCV-specific antibodies was tested indirectly using “neutralization of binding” (NOB) assays, in which antibodies were screened for their ability to prevent the binding of sE2 to mammalian cells [116]. Baumert and colleagues [117] used a recombinant baculovirus system to express the HCV structural proteins that formed viral-like particles (VLPs) to study antibody reactivity and inhibition of VLP-cell

Detection of autologous and heterologous neutralizing antibodies

Dissecting the humoral immune response to HCV at an individual level is a challenging endeavor; readily available gp sequences may represent certain viral genotypes but differ considerably from a patient's autologous viral quasispecies. Most studies are limited to establishing the heterologous cross-reactivity of nAbs and do not measure their efficacy to neutralize autologous circulating strains in the subject under test. Several studies have demonstrated that chronically infected subjects

Epitope specificity of the neutralizing antibody response

nAbs can exert their effect(s) by binding directly to virus particles and blocking subsequent interaction(s) with receptors or by inhibiting post-entry events, such as viral uncoating and subsequent replication (reviewed by Burton [147]). The former may occur by inducing conformational changes in the viral envelope that disable infection or by steric hindrance, physically shielding important viral interaction sites. The modes of action of HCV-specific nAbs have yet to be defined; however,

Effect of lipoproteins on the sensitivity of virus to neutralizing antibodies

Recent in vitro studies highlight the role of the VLDL pathway in the assembly and release of HCVcc particles [69], [70], [71]. These data support earlier observations reporting on the density and sedimentation properties of human plasma-derived virus, concluding that the virus exists in association with lipoproteins or immunoglobulins [73], [157], [158], [159]. Thosmsen and colleagues [160] reported that HCV RNA was associated with β-lipoproteins in sera, a finding that was later confirmed by

Inducing protective immunity in vivo

The propensity of HCV to establish chronic infection, to reinfect previously exposed individuals [164], to transmit directly by cell-cell routes in vitro [165], and to evolve neutralization escape variants [166] makes the development of an HCV vaccine a major challenge. Vaccine development has been hampered by the lack of a convenient small animal model [154], [167]. The existence of natural immunity to infection in some humans [168] and in chimpanzees [142], [169], [170], [171] is encouraging,

Summary

The processes of HCV entry and antibody-mediated neutralization are intimately linked. The high frequency of nAbs that inhibit E2-CD81 interaction(s) suggests that this is a major target for the humoral immune response. The observation that HCV can transmit to naive cells by means of CD81-dependent and -independent routes in vitro awaits further investigation to assess the significance in vivo but may offer new strategies for HCV to escape nAbs. The identification of CLDNs in the entry process

Acknowledgments

The authors thank all their colleagues for stimulating discussions over the years. Research in the McKeating laboratory is currently supported by Public Health Service grants AI40034 and AI50798, the Medical Research Council, and The Wellcome Trust.

References (185)

  • N.R. Webb et al.

    SR-BII, an isoform of the scavenger receptor BI containing an alternate cytoplasmic tail, mediates lipid transfer between high density lipoprotein and cells

    J Biol Chem

    (1998)
  • E.R. Eckhardt et al.

    High density lipoprotein uptake by scavenger receptor SR-BII

    J Biol Chem

    (2004)
  • E.R. Eckhardt et al.

    High density lipoprotein endocytosis by scavenger receptor SR-BII is clathrin-dependent and requires a carboxyl-terminal dileucine motif

    J Biol Chem

    (2006)
  • M. Dreux et al.

    High density lipoprotein inhibits hepatitis C virus-neutralizing antibodies by stimulating cell entry via activation of the scavenger receptor BI

    J Biol Chem

    (2006)
  • E.S. Barton et al.

    Junction adhesion molecule is a receptor for reovirus

    Cell

    (2001)
  • C.B. Coyne et al.

    CAR: a virus receptor within the tight junction

    Adv Drug Deliv Rev

    (2005)
  • C.B.B.J. Coyne

    Virus-induced Abl and Fyn kinase signals permit coxsackievirus entry through epithelial tight junctions

    Cell

    (2006)
  • M. Chen et al.

    Limited humoral immunity in hepatitis C virus infection

    Gastroenterology

    (1999)
  • K. Chang et al.

    Differential CD4(+) and CD8(+) T-cell responsiveness in hepatitis C virus infection

    Hepatology

    (2001)
  • S. Cooper et al.

    Analysis of a successful immune response against hepatitis C virus

    Immunity

    (1999)
  • M. Cucchiarini et al.

    Vigorous peripheral blood cytotoxic T cell response during the acute phase of hepatitis C virus infection

    Cell Immunol

    (2000)
  • M.W. Fried et al.

    Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

    N Engl J Med

    (2002)
  • K. Lindahl et al.

    High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C

    Hepatology

    (2005)
  • M. Lavie et al.

    Assembly of a functional HCV glycoprotein heterodimer

    Curr Issues Mol Biol

    (2007)
  • M. Hsu et al.

    Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles

    Proc Natl Acad Sci U S A

    (2003)
  • B. Bartosch et al.

    Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes

    J Exp Med

    (2003)
  • M. Flint et al.

    Diverse CD81 proteins support hepatitis C virus infection

    J Virol

    (2006)
  • D. Lavillette et al.

    Characterization of host-range and cell entry properties of the major genotypes and subtypes of hepatitis C virus

    Hepatology

    (2005)
  • T. Wakita et al.

    Production of infectious hepatitis C virus in tissue culture from a cloned viral genome

    Nat Med

    (2005)
  • J. Zhong et al.

    Robust hepatitis C virus infection in vitro

    Proc Natl Acad Sci U S A

    (2005)
  • B. Lindenbach et al.

    Complete replication of hepatitis C virus in cell culture

    Science

    (2005)
  • J. Dubuisson et al.

    Hepatitis C virus glycoprotein folding: disulfide bond formation and association with calnexin

    J Virol

    (1996)
  • Bartosch B, Ciczora Y, Montigny C, et al. E1 envelope glycoprotein from hepatitis C virus particles exists as a...
  • E. Blanchard et al.

    Hepatitis C virus entry depends on clathrin-mediated endocytosis

    J Virol

    (2006)
  • L. Meertens et al.

    Hepatitis C virus entry requires a critical postinternalization step and delivery to early endosomes via clathrin-coated vesicles

    J Virol

    (2006)
  • P. Pileri et al.

    Binding of hepatitis C virus to CD81

    Science

    (1998)
  • E. Scarselli et al.

    The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus

    EMBO J

    (2002)
  • J. Grove et al.

    Scavenger receptor BI and BII expression levels modulate hepatitis C virus infectivity

    J Virol

    (2007)
  • S. Kapadia et al.

    Initiation of hepatitis C virus infection is dependent on cholesterol and cooperativity between CD81 and scavenger receptor B type I

    J Virol

    (2007)
  • M. Evans et al.

    Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry

    Nature

    (2007)
  • H. Barth et al.

    Analysis of the effect of IL-12 therapy on immunoregulatory T-cell subsets in patients with chronic hepatitis C infection

    Hepatogastroenterology

    (2003)
  • H. Barth et al.

    Viral and cellular determinants of the hepatitis C virus envelope-heparan sulfate interaction

    J Virol

    (2006)
  • J. Zhang et al.

    CD81 is required for hepatitis C virus glycoprotein-mediated viral infection

    J Virol

    (2004)
  • J.A. McKeating et al.

    Diverse hepatitis C virus glycoproteins mediate viral infection in a CD81-dependent manner

    J Virol

    (2004)
  • A. Meola et al.

    Binding of hepatitis C virus E2 glycoprotein to CD81 does not correlate with species permissiveness to infection

    J Virol

    (2000)
  • M. Flint et al.

    Characterization of hepatitis C virus E2 glycoprotein interaction with a putative cellular receptor, CD81

    J Virol

    (1999)
  • Nakajima H, Cocquerel L, Levy S. Kinetic analysis of the interaction between HCV envelope glycoproteins with the...
  • K. Morikawa et al.

    The roles of CD81 and glycosaminoglycans in the adsorption and uptake of infectious HCV particles

    J Med Virol

    (2007)
  • G. Koutsoudakis et al.

    The level of CD81 cell surface expression is a key determinant for productive entry of hepatitis C virus into host cells

    J Virol

    (Nov 1 2006)
  • T. von Hahn et al.

    Oxidized low-density lipoprotein inhibits hepatitis C virus cell entry in human hepatoma cells

    Hepatology

    (2006)
  • Cited by (0)

    View full text